Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.5696
- Book/Share 9.1268
- PB 5.4047
- Debt/Equity 2.7512
- CurrentRatio 1.2663
- ROIC 0.1414
- MktCap 100159048928.0
- FreeCF/Share 7.5085
- PFCF 6.5455
- PE 16.6034
- Debt/Assets 0.5268
- DivYield 0.0504
- ROE 0.3465
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Scotiabank | -- | Sector Perform | -- | $45 | Nov. 13, 2025 |
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
What Is Happening With BMY Stock?
Published: December 01, 2025 by: Forbes
Sentiment: Positive
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 billion.
Read More
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.
Read More
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Read More
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
Read More
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
Read More
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers.
Read More
Why Bristol-Myers Squibb Remains Undervalued In 2025
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb remains my favorite, almost the only Big Pharma stock that hasn't left the accumulation zone. Sales of its "gem" in the cardiovascular franchise, Camzyos, were $296 million in Q3, up 89.7% year-over-year. On the other hand, my concerns about Opdivo Qvantig did not materialize, as its sales reached $67 million, double the Q2 figures.
Read More
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Read More
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
Read More
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
Published: November 05, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Negative
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent protection, leading to revenue declines despite a strong dividend yield. Recent acquisitions and new product launches have underperformed versus management's ambitious targets, raising concerns about BMY's growth prospects through 2030.
Read More
10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 38.01% by October 2026, with Lexinfintech Holdings leading potential returns.
Read More
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Read More
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.
Read More
Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
Read More
Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Rates Going Lower Next Week: Our Top 5% Dividend Picks Could Soar
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100